Viagra (sildenafil) increases blood flow to the genitals in women, just as it does in men. It can enhance physical arousal, improve vaginal lubrication, and make orgasm easier to achieve. However, it is not FDA-approved for use in women, and it does not boost sexual desire. The distinction between physical arousal and desire turns out to be critical for understanding who it helps and who it doesn’t.
How It Works in a Woman’s Body
Women’s genital tissue relies on the same blood flow mechanism that Viagra targets in men. During sexual stimulation, the body releases nitric oxide, a signaling molecule that relaxes smooth muscle in the clitoris and vaginal walls. This relaxation opens blood vessels, increasing blood flow to the clitoral tissue and the capillaries lining the vagina. The rush of blood to vaginal capillaries is actually what produces natural lubrication: fluid seeps through the vaginal wall as blood flow overwhelms the tissue’s ability to reabsorb it, typically producing 3 to 5 milliliters of lubrication.
Viagra amplifies this process by blocking an enzyme that normally breaks down the chemical signal telling smooth muscle to relax. The result is more blood flow for a longer period. In animal studies, sildenafil caused significant increases in genital blood flow and vaginal lubrication, though the effect was stronger when estrogen levels were adequate. This is an important detail: women with low estrogen (common after menopause) may get less benefit from Viagra alone.
What the Clinical Trials Found
A 12-week, double-blind, placebo-controlled trial published in The Journal of Urology tested sildenafil in 202 postmenopausal women with female sexual arousal disorder. Women took a 50 mg dose, adjustable to 25 or 100 mg. Overall, the drug produced statistically significant improvements in genital sensation during stimulation and satisfaction with sexual activity compared to placebo.
The results were more striking when researchers looked at a specific subgroup: women who had arousal problems but still felt sexual desire. In this group, 69% reported improved genital sensation on sildenafil versus 41% on placebo. Half reported improved satisfaction, compared to just 20% on placebo. Lubrication improved significantly too, with 82% reporting sufficient wetness on sildenafil versus 64% on placebo. The odds of achieving orgasm were more than four times higher on the drug compared to placebo, and overall sexual experience was nearly 11 times more likely to improve.
But here’s the catch: women who had low sexual desire alongside their arousal problems saw no significant benefit. Viagra works on the plumbing, not the wanting. If the underlying issue is a lack of interest in sex, increasing blood flow to the genitals doesn’t solve the problem.
Viagra Does Not Increase Desire
This is the most important distinction for anyone considering Viagra as a woman. The drug works on physical arousal only. It does not affect the brain pathways involved in sexual desire, mood, or motivation. For women whose primary complaint is low libido, Viagra is the wrong tool.
Two FDA-approved medications do target desire in women, and they work completely differently. Flibanserin (sold as Addyi) is a daily pill that acts on serotonin receptors in the brain, increasing sexual desire and reducing distress about low libido. Bremelanotide (Vyleesi) is a self-administered injection taken before sexual activity that also works through the central nervous system. Neither of these drugs affects genital blood flow. They address the “wanting” side of the equation, while Viagra addresses the “responding” side.
Off-Label Uses Beyond Sexual Function
Some fertility specialists prescribe vaginal sildenafil suppositories to women undergoing IVF who have trouble building a thick enough uterine lining. A thin endometrial lining makes it harder for embryos to implant. In a study of 105 women under 40 who had at least two prior failed IVF cycles with thin linings (under 9 mm), vaginal sildenafil suppositories (25 mg, four times daily) helped 70% of them reach adequate thickness. That group went on to have a 45% ongoing pregnancy rate, compared to 0% among the women whose lining didn’t respond.
Researchers are also investigating vaginal sildenafil for severe menstrual cramps. The theory is that sildenafil could relax the uterine muscle contractions responsible for cramping pain, using the same blood vessel relaxation mechanism it employs elsewhere. A phase 1 clinical trial is evaluating whether a single 100 mg vaginal suppository reduces uterine contractions and acute menstrual pain over four hours. Early data has suggested acute pain relief, but the research is still in early stages.
Side Effects in Women
The side effects women experience are generally the same ones men report: headaches, facial flushing, nasal congestion, and visual disturbances. These are all consequences of blood vessel dilation throughout the body. In the 12-week clinical trial, sildenafil was considered well-tolerated at doses of 25 to 100 mg, and no unexpected safety signals emerged in the female participants.
The most serious safety concern applies equally to men and women: sildenafil must never be combined with nitrate medications. Nitrates are prescribed for chest pain and heart conditions and also include recreational substances like amyl nitrite (“poppers”). The combination can cause a sudden, dangerous drop in blood pressure. This interaction is potentially life-threatening. People over 65, those with liver or kidney problems, or anyone taking certain medications (including some antibiotics, antifungals, and HIV medications) may also clear sildenafil more slowly, increasing the risk and duration of side effects.
Regulatory Status
Viagra is not FDA-approved for use in women. Any use by women is considered off-label, meaning a doctor prescribes it based on clinical judgment rather than formal regulatory approval. Pfizer pursued clinical trials in women but ultimately did not seek approval, partly because the drug failed to show benefit in women with low desire, who make up a large portion of those seeking help for sexual difficulties.
A topical sildenafil cream (3.6% concentration) is currently being studied in a multi-center clinical trial for premenopausal women with arousal disorder. Patients apply a small amount up to nine times per month. This approach delivers the drug directly to genital tissue, potentially reducing whole-body side effects while concentrating the blood flow effects where they matter. Whether this formulation will eventually gain FDA approval remains to be seen.